AI Drug Discovery
Isomorphic Labs
by Isomorphic Labs Ltd.
Reimagining drug discovery with AI to design medicines faster than ever before
Category
AI Drug Discovery
Founded
2021
Headquarters
London, United Kingdom
Overview
Isomorphic Labs is a commercial spin-off from Google DeepMind focused entirely on applying AI to accelerate drug discovery. The company builds on DeepMind's breakthroughs in structural biology — including AlphaFold — and extends them into a full drug design platform that predicts how small molecules interact with biological targets, models protein dynamics, and generates candidate therapeutics with optimized drug-like properties. Pharmaceutical partners engage Isomorphic Labs through strategic research collaborations where AI-driven target-to-candidate workflows compress timelines that traditionally take years. In 2024 the company announced major research collaborations with Eli Lilly and Novartis worth up to $2.9 billion in potential milestones, establishing it as one of the highest-value AI drug discovery partnerships in the industry. Isomorphic Labs' core differentiator is its privileged relationship with Google DeepMind, giving it first access to frontier foundation models for biology — including AlphaFold 3 — and Google's TPU infrastructure for large-scale AI training. This computational advantage, combined with a team drawn from DeepMind, pharma, and academia, positions the company uniquely at the intersection of frontier AI and drug design.
Key Features
Generative Molecular Design
AI generates novel molecular structures optimized for specific biological targets and desired properties.
Binding Affinity Prediction
Deep learning models predict drug-target binding affinities with near-experimental accuracy.
De Novo Drug Design
Design entirely new drug molecules from scratch using generative AI trained on billions of molecular interactions.
ADMET Profiling
Comprehensive in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles.
Multi-Target Optimization
Simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches.
Pros & Cons
Pros
- +Multi-target drug discovery platform identifies candidates across oncology, rare diseases, and infectious disease
- +Closed-loop integration of wet-lab experiments with AI models continuously improves prediction accuracy
- +Proprietary biological datasets spanning petabytes of experimental data enable novel target discovery
- +AI-powered virtual screening accelerates hit identification by 10-100x compared to traditional high-throughput screening
- +Strategic pharma partnerships validate platform capabilities with billion-dollar deal values
- +Reduces preclinical development timelines from years to months with computational candidate optimization
Cons
- −Enterprise pricing accessible only to large pharma — prohibitive for academic labs and small biotechs
- −Long sales cycles and custom integration requirements extend time to value for new customers
- −Black-box nature of deep learning models creates interpretability challenges for regulatory submissions
- −Computational predictions still require extensive wet-lab validation before clinical advancement
- −Requires substantial proprietary training data to achieve meaningful prediction accuracy improvement
Use Cases
Virtual Screening & Hit Identification
AI-powered virtual screening of billion-scale compound libraries to identify drug candidates in days instead of months.
Target Identification & Validation
Machine learning models identify novel drug targets from multi-omics data and validate their therapeutic potential.
Lead Optimization
Computational optimization of lead compounds for potency, selectivity, ADMET properties, and synthesizability.